X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 96.26 percent increase over losses of $(5.89) per share from the same period last year. The company reported quarterly sales of $2.568 million which beat the analyst consensus estimate of $1.733 million by 48.18 percent. This is a 79.08 percent increase over sales of $1.434 million the same period last year.